Company Profile
Black Diamond Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Black Diamond Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Black Diamond Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Black Diamond Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Black Diamond Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
BDTX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Black Diamond is still very much a silevertinib company. The Q2 clinical update in non-classical EGFRm NSCLC and the planned randomized Phase 2 in EGFR-altered disease are the milestones that matter because they tell us whether the drug can move beyond a single proof-of-concept moment.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Black Diamond Therapeutics
- 02
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Source: Black Diamond Therapeutics
- 03
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Source: Black Diamond Therapeutics
- 04
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Source: Black Diamond Therapeutics
- 05
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Source: Black Diamond Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.